+252.5%
LIN vs MRNA
+561.6%
-309.0%
-32.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.0% | -2.2% | +1.3% | -0.9% |
| 7D | -2.1% | +5.5% | -7.6% | -2.3% |
| 30D | -2.4% | +158.7% | -161.2% | -7.0% |
| 3M | -5.6% | +182.1% | -187.7% | -10.5% |
| 6M | -3.4% | +151.8% | -155.2% | -8.1% |
| YTD | +13.1% | +393.6% | -380.5% | +4.0% |
| 1Y | +2.5% | +499.5% | -497.0% | -6.9% |
| 3Y | +27.6% | +29.3% | -1.7% | +21.9% |
| 5Y | +63.0% | -65.1% | +128.1% | +59.1% |
| All | +252.5% | +561.6% | -309.0% | +211.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling